Cumulus Neuroscience publishes VEP plasticity study in Nature — wireless dry-EEG validated for Phase 1 clinical trial biomarkers
Summary
Cumulus Neuroscience published a study in Nature demonstrating visual evoked potential (VEP) modulation assessment of experience-dependent plasticity recorded via their wireless dry-EEG headset in Phase 1 clinical settings. The study validates Cumulus's wireless EEG as a tool for measuring cortical plasticity — a key mechanism underlying antidepressant, anxiolytic, and neuroprotective drug effects — as a biomarker in clinical drug trials. The Nature publication establishes Cumulus as a clinical-grade wearable EEG tool for pharmaceutical development, not just consumer monitoring.
Why it matters
Nature publication of VEP plasticity measurement from a wireless dry-EEG headset in Phase 1 clinical units is the regulatory and scientific validation that pharmaceutical companies need to adopt Cumulus as a clinical trial biomarker tool. VEP-based plasticity measurement provides objective neurophysiological evidence of drug CNS activity — a biomarker that Phase 1 teams can use to screen for CNS engagement before committing to larger Phase 2 trials.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial